SAN FRANCISCO--(BUSINESS WIRE)--YourChoice Therapeutics, a San Francisco biotech startup developing the first hormone-free male birth control pill, announced today that Gunda Georg, YCT-529’s co-inventor, provided an update on its phase 1a clinical study for the first hormone-free male birth control pill, YCT-529, at the American Chemical Society (ACS) 2024 Spring Meeting.

旧金山--（商业新闻短讯）--YourChoice Therapeutics是旧金山一家开发第一种无激素男性避孕药的生物技术初创公司，今天宣布，YCT-529的共同发明人冈达·乔治（GundaGeorg）在美国化学学会（ACS）2024年春季会议上为第一种无激素男性避孕药YCT-529提供了1a期临床研究的最新信息。

The ACS meeting is being held in New Orleans and concludes on March 21, 2024..

ACS会议将于2024年3月21日在新奥尔良举行。。

Dr. Georg provided details about YCT-529, a drug discovered in her group that has progressed into a phase 1 study, which began in December 2023. Her presentation, “Discovery and development of a male pill: Are we finally getting there?” was on March 18. The phase 1a study investigates the safety, tolerability, pharmacokinetics, and pharmacodynamics of single, ascending oral doses of YCT-529 in 16 participants.

Georg博士提供了有关YCT-529的详细信息，YCT-529是在她的小组中发现的一种药物，已进入2023年12月开始的第一阶段研究。她于3月18日发表了题为“男性避孕药的发现和开发：我们终于到了吗？”的演讲。1a期研究调查了16名参与者单次口服递增剂量YCT-529的安全性，耐受性，药代动力学和药效学。

YourChoice Therapeutics expects to complete the study by mid-2024..

YourChoice Therapeutics预计在2024年年中完成这项研究。。

“The phase 1a study for YCT-529 is progressing well,” said Gunda Georg, PhD, Regents Professor at the University of Minnesota’s College of Pharmacy and founding director of the Institutes for Therapeutics Discovery and Development. “March is the mid-point of the study. It’s also Women’s History Month, creating an opportunity to highlight the need for contraceptive equity.

“YCT-529的1a期研究进展顺利，”明尼苏达大学药学院Regents教授、治疗发现与开发研究所创始主任GundaGeorg博士说。“三月是研究的中点。也是妇女历史月，为强调避孕公平的必要性创造了机会。

The future of pregnancy prevention is shared responsibility. I’m pleased to be a part of that future.”.

预防怀孕的未来是共同的责任。我很高兴成为未来的一部分。”。

YCT-529 is a hormone-free birth control candidate currently under investigation. It prevents sperm production by blocking access to a form of vitamin A, called retinoic acid, in the testes. Multiple independent studies validate the mechanism of action, which researchers identified decades ago. Preclinical studies in mice showed that YCT-529 was as effective or better than the human female birth control pill in preventing pregnancies and 100% reversible without side effects..

YCT-529是目前正在调查的无激素节育候选人。它通过阻断睾丸中一种称为视黄酸的维生素a来阻止精子的产生。多项独立研究验证了研究人员几十年前确定的作用机制。对小鼠的临床前研究表明，YCT-529在预防怀孕方面与人类女性避孕药一样有效或更好，并且100%可逆，没有副作用。。

“Men and women want more birth control options, and they want them to be hormone-free,” said Akash Bakshi, co-founder and CEO of YourChoice Therapeutics. “Gunda’s work to deliver the first hormone-free birth control pill is ground-breaking and could shepherd a transformative—and much needed—shift toward shared responsibility, choice, and reproductive equality.

YourChoice Therapeutics联合创始人兼首席执行官阿卡什·巴克什（Akash Bakshi）表示：“男性和女性都希望有更多的节育选择，而且他们希望这些选择不含激素。”。“冈达（Gunda）推出第一种无激素避孕药的工作具有开创性意义，可能会引导人们朝着共同责任、选择和生殖平等的方向转变，这是一个变革性的、急需的转变。

Men want to help, and we’re working collaboratively with Gunda to give them more options to do so.”.

男性想要帮助，我们正在与冈达合作，为他们提供更多的选择。”。

About YCT-529

关于YCT-529

Researchers have understood for decades that vitamin A is essential for male fertility. YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents the production of sperm cells in the testes as well as their release by blocking RAR-alpha (one of three nuclear receptors that bind retinoic acid, a form of vitamin A).

几十年来，研究人员一直认为维生素A对男性生育能力至关重要。YCT-529是一种视黄酸受体α（RARα）抑制剂，可通过阻断RARα（结合视黄酸（维生素a的一种形式）的三种核受体之一）来阻止睾丸中精子细胞的产生及其释放。

Several preclinical studies have shown that YCT-529 is 99% effective at preventing mouse pregnancies and 100% reversible. YourChoice Therapeutics developed YCT-529 in collaboration with Dr. Gunda Georg, a globally recognized medicinal chemist, and awardee of one of the largest NIH-funded Contraceptive Centers.

几项临床前研究表明，YCT-529在预防小鼠怀孕方面有效率为99%，可逆性为100%。YourChoice Therapeutics与全球公认的药物化学家Gunda Georg博士合作开发了YCT-529，他是美国国立卫生研究院资助的最大避孕中心之一的获奖者。

The Male Contraceptive Initiative (MCI) has been committed to funding the early research and YCT-529’s Phase 1a clinical trial in men, which is underway at Quotient Sciences in the UK. More information about the trial can be found at clinicaltrials.gov, NCT06094283..

男性避孕倡议（MCI）一直致力于资助早期研究和YCT-529的男性1a期临床试验，该试验正在英国商科学公司进行。有关该试验的更多信息，请访问clinicaltrials.gov，NCT06094283。。

About YourChoice Therapeutics

关于YourChoice Therapeutics

YourChoice Therapeutics is an early-stage biopharmaceutical company focused on developing the first hormone-free birth control pill for men. Based in San Francisco, the company is currently studying YCT-529 in a Phase 1a clinical trial. In preclinical studies, YCT-529 performed as effectively or better than the female birth control pill.

YourChoice Therapeutics是一家早期生物制药公司，专注于开发第一种男性无激素避孕药。该公司位于旧金山，目前正在1a期临床试验中研究YCT-529。在临床前研究中，YCT-529的表现与女性避孕药一样有效或更好。

Future programs will apply the company’s patented therapeutic platform to develop hormone-free family-planning products for women. Established in 2018, the company raised a $15M Series A in 2022. For more information, visit www.yourchoicetx.com and follow the company on LinkedIn..

未来的项目将应用该公司的专利治疗平台为女性开发无激素计划生育产品。该公司成立于2018年，于2022年筹集了1500万美元的a系列资金。有关更多信息，请访问www.yourchoicetx.com并在LinkedIn上关注该公司。。